Press Release

2025 / 01 / 16

San Francisco Examiner

Triplebar Bio Strengthens Advisory Board with the Addition of Renowned Experts

Emeryville, CA – 12/10/2025 – Triplebar, a pioneering biotechnology company based in Emeryville which is focused on developing cost effective and effective therapies for serious diseases, today announced the addition of two accomplished industry leaders to its Advisory Board – Dr. Bernard Coulie and Dr. Holger Wesche.

“We are grateful to welcome Dr. Coulie and Dr. Wesche to our Advisory Board,” said Maria Cho, CEO of Triplebar. “Their impressive experience and scientific expertise will be invaluable as we advance our pipeline of transformative therapies. We are confident that their insights will accelerate our efforts to deliver life-changing treatments to patients in need.”

Dr. Bernard Coulie is a seasoned pharmaceutical executive with nearly 25 years of experience in drug development. He has successfully advanced programs from early discovery to late-stage clinical trials. Dr. Coulie serves as President and CEO of Pliant Therapeutics and has previously held key leadership roles at ActoGeniX and Johnson & Johnson. Dr. Coulie holds an M.D. and Ph.D. from the University of Leuven, Belgium, and an MBA from Vlerick Management School.

Dr. Holger Wesche is a biotech executive with over 25 years of experience in drug discovery and development. He has held leadership positions at Harpoon Therapeutics and Amgen, where he focused on oncology and immunology. Dr. Wesche has a strong track record in target identification and validation, as well as in the development of novel therapeutic platforms. He received his Ph.D. in Biochemistry and Immunology from the University of Hannover, Germany. Dr. Holger Welsche

Dr. Bernard Coulie